NIH funds and conducts biomedical research, shaping U.S. public health through intramural science and extramural grants.
Kennedy has led a push to pull government flu-vaccine advertising amid a broader shift at HHS, with emails showing internal debate and political direction shaping public-health messaging during a severe flu season. The disclosures show tension between Kennedy’s policy moves and CDC leadership as a new administration implements its agenda.
Anthropic is launching an internal drug-discovery program to develop AI tools for life sciences, focusing on neglected diseases. The effort aims to create drug-discovery capabilities in-house and partner with industry, while navigating the costly regulatory path and uncertain clinical development timelines.
Pharma licensing assets from China has become the main source for Western drug developers, with Evaluate projecting China-based deals will exceed two-thirds of industry value this year. The shift prompts concerns about hollowing out U.S. biotech capacity while supporters argue it accelerates patient access to new medicines.
The Senate has held a confirmation hearing for Dr. Erica Schwartz, the nominee to lead the CDC, amid questions about how she would balance scientific independence with pressure from the administration on vaccine policy. Her background spans the Coast Guard and the surgeon general’s office, with the agency facing staffing turmoil and political scrutiny.
The Pentagon has rolled out annual testosterone screenings for service members aged 30 and older, with younger troops able to volunteer. Officials describe the measure as part of maintaining a “strong, resilient and capable” fighting force, while experts warn on possible health risks and ethical concerns about medical oversight.
The military is screening for low testosterone and offering therapy to qualified troops. Experts warn against overprescribing and emphasize that treatment targets those with clinically diagnosed deficiencies.
The Justice Department is conducting a compliance review of Harvard University’s foreign funding disclosures to ensure it does not discriminate against American students in financial aid. Harvard says it does not unlawfully discriminate and is reviewing the DOJ notice as part of ongoing scrutiny of foreign money in U.S. higher education.